knowledge -WSS

knowledge

author：fashion 2025-09-30 02:09:19 - browse：8

There’s a specter haunting Wall Street.

It started in biotech, where companies making drugs for the obesity-related liver disease NASH saw their valuations crash on the assumption that GLP-1 weight loss treatments would cut them out of the market. Then the Ozempic panic came for dialysis firms, whose stocks fell about 20% in a single day on the news that Novo Nordisk’s medicine had delayed the progression of kidney disease in a study enrolling people with type 2 diabetes.

Now analysts from every sector are cranking out research notes on the disparate, dramatic, and often debatable implications of GLP-1 drugs’ growing popularity, said Jared Holz, a health care specialist at Mizuho Securities. Buy Bumble, sell McDonald’s. Short Pepsi, go long Louis Vuitton. Put your money in sectors that cater to a svelte and sated brand of consumer, and get out of the ones that rely on excess and compulsion.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： Kellogg’s is going to war over Mexico’s nutrition label rules

hotspot

WSS

Roche's accidental data boosts hopes for anti

California store owner shot dead in dispute over displaying Pride flag: Police

Wegovy improves function in certain heart failure patients

Listen: Vivek Ramaswamy's star turn & leaky drug data

Fed up with FDA, ALS advocates consider a take

DeSantis wants to import drugs. Biden’s FDA blasted his plan

focus

knowledge

leisure time

Hepatitis C has a cure — but many Americans still lack access to it

Assistant physicians can help address the primary care shortage

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Patients, doctors press FTC to beef up hospital merger scrutiny

Drug repurposing or repositioning? The language matters

Eli Lilly CEO gives to Mike Pence presidential super PAC

Novavax promises a turnaround & Lilly roils the obesity market

CDC says it’s too soon to assess risk posed by Covid subvariant

Duchenne breakthrough therapy leaves behind pioneering families

FDA weighs limits of animal data in assessing artificial wombs

explore

Republicans love RFK Jr. What's that tell us about health in 2024?

Vivek Ramaswamy made waves in the debate, much as in biotech

FDA panel to weigh safety of artificial wombs for preterm births

Why the drug industry's warnings on the IRA's impact fall short

What happened to the House vote on health price transparency?

House panel takes first step toward fixing drug shortages

hotspot

focus

hotspot

hotspot